RC
GCVRZ

RegentAtlantic Capital’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

RegentAtlantic Capital’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-642
Closed -$507 – 1238
2014
Q4 		$507 Buy
+642
New +$439 ﹤0.01% 1203

Other funds holding GCVRZ

WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

RegentAtlantic Capital's GCVRZ Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2015, closing a stake of 642 shares — an estimated $507 sold.

RegentAtlantic Capital first reported a position in GCVRZ in Q4 2014 and held it in 1 quarter. The position peaked at $507 in Q4 2014. 115 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Sanofi Contingent Value Rights position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 642 Sanofi Contingent Value Rights shares in Q1 2015, an estimated $507.
  • RegentAtlantic Capital first reported a position in Sanofi Contingent Value Rights in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Sanofi Contingent Value Rights position peaked at $507 in Q4 2014.
  • 115 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.